Corporate research spillovers help explain a central challenge in industrial R&D: scientific work may create knowledge that a company can use in its own inventions, but that knowledge can also benefit competitors. For automation manufacturers, technology suppliers, and other industrial firms, this tension matters when deciding how to balance upstream research with product development and commercialization.
A study of U.S. firms from 1980 to 2015 examines this trade-off through scientific publications and patent citations. Its findings suggest that corporate science can be both privately valuable and socially useful, while growing use of company research by rivals may weaken firms’ incentives to publish more.
Why companies invest in scientific research
Research and development includes activities at different points in the innovation process. Scientific research generates knowledge that may inform future technologies; development applies knowledge to create or improve products and processes. Although the two are connected, a company may not capture the same returns from each.
Research can contribute to a firm’s own inventions. If scientific findings help engineers or inventors solve technical problems, they can support downstream innovation. Research may also have broader benefits: once published, findings can be read, cited, and used by other organizations, including competitors.
These opposing effects shape the potential business case. A firm has stronger reasons to sustain research when its own inventions benefit from the knowledge. But if close rivals use that research to develop competing products, some of the value may accrue outside the firm that paid for the work.
How the study measures corporate research spillovers
The analysis covers 4,090 publicly traded U.S. firms with R&D spending and at least one patent during the study period. Researchers assembled a dataset of approximately 800,000 scientific publications associated with the companies and their majority-owned subsidiaries, then examined patent references to those publications.
Patent citations provide an indicator of whether scientific knowledge is being used in invention. A company’s patent citing its own scientific publication is treated as evidence of internal use. Citations from other companies’ patents indicate external use, or a potential knowledge spillover. The study also distinguishes citations from product-market rivals from citations by other firms, recognizing that external use may have different competitive implications depending on who is using the knowledge.
This approach measures the relationship between research output and its use; it does not establish that a particular citation caused a company to invest more or less. The findings are associations observed across firms and years, considered alongside controls for firm characteristics.
Internal use is linked to research output
Across the analysis, firms produced more scientific publications when their earlier research was cited in their own patents. The relationship remained after accounting for firm-specific differences and changing business characteristics. It was stronger when citations came from patents using more recent research, and was also more pronounced for research or patents classified as higher quality under the study’s measures.
This pattern is consistent with research functioning as an input to a company’s invention process. When managers can connect scientific work to the firm’s own patenting activity, the case for continuing that work may be easier to make. For industrial organizations, that connection can be relevant when evaluating research programs whose outcomes may be distant from immediate product launches: potential value includes the knowledge’s contribution to later inventions, not just a near-term commercial deliverable.
Why competitor use may discourage research
The study finds a different relationship for spillovers to product-market rivals. Greater use of a firm’s publications by its rivals is associated with lower publication output, and this relationship became stronger over the period examined. The share of corporate citations coming from rivals in the same four-digit industry classification rose from below 10% early in the period to 30% by its end.
Meanwhile, use of a firm’s research in its own inventions remained relatively stable. The authors estimate that the increased incidence and importance of spillovers to rivals could explain up to 45% of the estimated decline in corporate publication rates. This is a substantial contribution, but not a complete explanation of the decline.
The distinction between competitors and other external users is important. A citation from another organization can signal that research is relevant, but use by a direct rival may also help that rival improve its position in the product market. In that situation, the original company’s research can create value beyond its boundaries while reducing the share of potential benefits it can capture.
What the findings mean for industrial R&D decisions
The evidence does not imply that firms should avoid research or that every external citation represents lost revenue. Rather, it highlights a strategic question for technical decision-makers: how does the expected contribution of research to internal invention compare with the risk that useful knowledge will benefit close competitors?
- Track pathways to internal use. Connect research outputs with the patents, technologies, or development efforts that draw on them. The study’s findings indicate that internal use is associated with higher research output.
- Consider who benefits from published knowledge. External citations are not all equivalent. Use by product-market rivals may carry different competitive implications from use by organizations outside the firm’s competitive space.
- Assess research and development as a portfolio. A shift toward development can change the composition of R&D, but research may provide knowledge that supports later invention. Decisions should account for this connection as well as near-term development goals.
- Interpret publication trends in context. The study finds variation across industries, including a different pattern in life sciences than in several other sectors. A single company-wide assumption may not capture differences among technical fields.
Patent citations offer a way to examine how scientific knowledge moves into invention, but they are an indicator of use, not a complete measure of research value or commercial return. Publication counts also do not capture every form of confidential or unpublished research. The results are therefore most useful as evidence about broad relationships, rather than as a direct forecast for an individual company.
Balancing research value and spillover risk
The practical implication is that corporate research incentives depend on both sides of the knowledge equation: the value a firm realizes through its own inventions and the value that spills over to competitors. The study links internal use with greater scientific output and rival use with lower output, against a longer-term shift from research toward development. For industrial leaders, connecting research to downstream innovation while recognizing competitive spillover exposure can support more informed R&D portfolio decisions.